Neko Health Secures $260M in Series B Funding for Preventative Healthcare Expansion

Neko Health, a preventative healthcare startup co-founded by Spotify CEO Daniel Ek, has raised $260 million in a Series B financing round led by Lightspeed Venture Partners. The funding will support the company's expansion plans in the United States and Europe, as well as fuel research and development efforts in health diagnostics.

Revolutionary Full-Body Scan Service

Neko Health offers a comprehensive 15-minute full-body scan service designed to detect various health conditions, including cancers and cardiovascular diseases. The scan, which currently costs £299 (approximately $372), utilizes a combination of proprietary and third-party medical devices to perform noninvasive checks on multiple aspects of a patient's health.

The company's innovative approach combines hardware and software to capture data on various health parameters. Following the scan, customers consult with a doctor to discuss their results, promoting a shift from reactive to proactive healthcare through early detection and preventative measures.

Impressive Early Results and Expansion Plans

Since launching its service in February 2023, Neko Health has demonstrated promising results:

• 2,707 people were scanned in the first year of operation
• Nearly 80% of participants were found to be in good health
• 6.6% of scans revealed significant health conditions
• 1% of participants received potentially life-saving interventions

The company currently operates two scanning sites in Stockholm and London, with plans to expand its presence in the coming months. Neko reports having performed 10,000 scans across its existing locations, with a waiting list of 100,000 potential customers, indicating strong demand for its services.

Research and Development Initiatives

A portion of the newly secured funding will be allocated to research and development in health diagnostics. Neko Health is currently involved in three clinical studies in Sweden, focusing on:

1. The impact of Type 1 diabetes on the vascular system
2. Methods for detecting heart failure risk
3. Strategies to prevent cardiovascular and pulmonary diseases

These research efforts align with the company's mission to advance preventative healthcare and early disease detection.